Atherosclerosis
Volume 199, Issue 2 , Pages 397-401 , August 2008

Cystatin C—A marker of peripheral atherosclerotic disease?

  • J. Arpegård

      Affiliations

    • Department of Medicine, Division of Emergency Medicine, Karolinska University Hospital-Solna, Stockholm, Sweden
    • ,
  • J. Östergren

      Affiliations

    • Department of Medicine, Division of Emergency Medicine, Karolinska University Hospital-Solna, Stockholm, Sweden
    • ,
  • U. de Faire

      Affiliations

    • Department of Cardiology, Karolinska Institute Stockholm, Sweden
    • Karolinska University Hospital-Solna, Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institute Stockholm, Sweden
    • ,
  • L.-O. Hansson

      Affiliations

    • Department of Clinical Chemistry Akademiska University Hospital, Uppsala, Sweden
    • ,
  • P. Svensson

      Affiliations

    • Department of Medicine, Division of Emergency Medicine, Karolinska University Hospital-Solna, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Department of Emergency Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden. Tel.: +46 851775543; fax: +46 851775855.

Received 28 August 2007 ,Revised 24 October 2007 ,Accepted 15 November 2007.

References 

  1. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996;56:409–414
  2. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin C. creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000;37(Part 1):49–59
  3. Norlund L, Fex G, Lanke J, et al. Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2-microglobulin/cystatin C-ratio. Scand J Clin Lab Invest. 1997;57:463–470
  4. Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A. Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest. 1999;59:587–592
  5. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421
  6. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321–327
  7. Eriksson P, Deguchi H, Samnegard A, et al. Human evidence that the cystatin c gene is implicated in focal progression of coronary artery disease. Atheroscler Thromb Vasc Biol. 2004;24:551–557
  8. Svensson P, De Faire U, Niklasson U, Östergren J. Office blood pressure underestimates ambulatory blood pressure in peripheral arterial disease in comparison to healthy controls. J Hum Hypertens. 2004;18:193–200
  9. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23:402–408
  10. Rose G. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645–658
  11. Theodorsen L. Dry reagent technology. Kodak Ektachem 700 XR in clinical enzymology. Scand J Clin Lab Invest Suppl. 1993;215:101–111
  12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  14. Levey AS, Greene T. Expressing the MDRD Study Equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values [abstract]. J Am Soc Nephrol. 2005;16:69A
  15. National Kidney Foundation . Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):S1–S266
  16. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods:implications for clinical and epidemiological applications. Clin Chem. 2000;46:461–468
  17. Albert MA, Rifai N, Ridker PM. Plasma levels of Cystatin C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med. 2001;6:145–149
  18. Shi GS, Sukhova GK, Grubb A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999;104:1191–1197
  19. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  20. Volanakis JE. Human C-reactive protein: expression, structure and function. Mol Immunol. 2001;38:189–197
  21. Liu J, Sukhova GK, Sun JS, et al. Lysosomal cystein proteases in atherosclerosis. Atheroscler Thromb Vasc Biol. 2004;24:1359–1366
  22. Chapman HA, Reise RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63–88

PII: S0021-9150(07)00743-5

doi: 10.1016/j.atherosclerosis.2007.11.025

Atherosclerosis
Volume 199, Issue 2 , Pages 397-401 , August 2008

Article Tools

* Image Usage & Resolution